| Aug 13 |
Marinus Pharmaceuticals GAAP EPS of -$0.63 misses by $0.04, revenue of $8.06M misses by $1.45M
|
| Aug 13 |
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
|
| Aug 12 |
Marinus Pharmaceuticals Q2 2024 Earnings Preview
|
| Aug 8 |
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 6 |
3 Biotech Stocks to Sell in August Before They Crash & Burn
|
| Jul 31 |
The past three years for Marinus Pharmaceuticals (NASDAQ:MRNS) investors has not been profitable
|
| Jul 30 |
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
|
| Jul 25 |
Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts?
|
| Jul 18 |
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
|
| Jun 24 |
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
|
